Taurine can Decrease Phosphorylated Tau Protein Levels in Alzheimer's Model Rats' Brains

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Microtubule formation is regulated by Tau proteins, crucial for neuronal structure.
• Hyperphosphorylated Tau leads to neuron starvation and cell death, implicated in neurodegenerative diseases.
• Taurine, an amino acid abundant in the brain, exhibits known neuroprotective properties.

Purpose of the Study:

• To investigate the neuroprotective effects of Taurine on phosphorylated Tau protein levels in the cerebellum and prefrontal cortex.
• To determine if Taurine administration, before or after scopolamine induction, can mitigate Tau hyperphosphorylation.

Main Methods:

• Adult male Wistar rats were divided into nine groups.
• Taurine (25, 50, 100 mg/kg/day) was administered before or after scopolamine injection for two weeks.
• Phosphorylated Tau protein levels were quantified using ELISA in brain tissues.

Main Results:

• Taurine pretreatment at all doses significantly reduced scopolamine-induced Tau hyperphosphorylation in both cerebellum and prefrontal cortex (p < 0.001).
• High-dose Taurine (100 mg/kg/day) administered post-scopolamine also significantly decreased phosphorylated Tau levels (cerebellum: p < 0.01; prefrontal cortex: p < 0.05).
• Lower Taurine doses (25, 50 mg/kg/day) after scopolamine showed no significant effect on Tau phosphorylation.

Conclusions:

• Taurine effectively attenuates scopolamine-induced increases in phosphorylated Tau protein in rat brain regions.
• Taurine administration, particularly as a pretreatment, offers a promising strategy for neuronal protection against Tau pathology.